HLA-Bw4-I-80 Isoform Differentially Influences Clinical Outcome As Compared to HLA-Bw4-T-80 and HLA-A-Bw4 Isoforms in Rituximab or Dinutuximab-Based Cancer Immunotherapy
Killer-cell immunoglobulin-like receptors (KIRs) are a family of glycoproteins expressed primarily on natural killer cells that can regulate their function. Inhibitory KIRs recognize MHC class I molecules (KIR-ligands) as ligands. We have reported associations of KIRs and KIR-ligands for patients in...
| Main Authors: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2017-06-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | http://journal.frontiersin.org/article/10.3389/fimmu.2017.00675/full |
| _version_ | 1819050104582045696 |
|---|---|
| author | Amy K. Erbe Wei Wang Patrick K. Reville Lakeesha Carmichael KyungMann Kim Eneida A. Mendonca Yiqiang Song Jacquelyn A. Hank Wendy B. London Arlene Naranjo Fangxin Hong Michael D. Hogarty John M. Maris Julie R. Park Julie R. Park M. F. Ozkaynak Jeffrey S. Miller Andrew L. Gilman Brad Kahl Alice L. Yu Alice L. Yu Paul M. Sondel Paul M. Sondel |
| author_facet | Amy K. Erbe Wei Wang Patrick K. Reville Lakeesha Carmichael KyungMann Kim Eneida A. Mendonca Yiqiang Song Jacquelyn A. Hank Wendy B. London Arlene Naranjo Fangxin Hong Michael D. Hogarty John M. Maris Julie R. Park Julie R. Park M. F. Ozkaynak Jeffrey S. Miller Andrew L. Gilman Brad Kahl Alice L. Yu Alice L. Yu Paul M. Sondel Paul M. Sondel |
| author_sort | Amy K. Erbe |
| collection | DOAJ |
| description | Killer-cell immunoglobulin-like receptors (KIRs) are a family of glycoproteins expressed primarily on natural killer cells that can regulate their function. Inhibitory KIRs recognize MHC class I molecules (KIR-ligands) as ligands. We have reported associations of KIRs and KIR-ligands for patients in two monoclonal antibody (mAb)-based trials: (1) A Children’s Oncology Group (COG) trial for children with high-risk neuroblastoma randomized to immunotherapy treatment with dinutuximab (anti-GD2 mAb) + GM-CSF + IL-2 + isotretinion or to treatment with isotretinoin alone and (2) An Eastern Cooperative Oncology Group (ECOG) trial for adults with low-tumor burden follicular lymphoma responding to an induction course of rituximab (anti-CD20 mAb) and randomized to treatment with maintenance rituximab or no-maintenance rituximab. In each trial, certain KIR/KIR-ligand genotypes were associated with clinical benefit for patients randomized to immunotherapy treatment (immunotherapy in COG; maintenance rituximab in ECOG) as compared to patients that did not receive the immunotherapy [isotretinoin alone (COG); no-maintenance (ECOG)]. Namely, patients with both KIR3DL1 and its HLA-Bw4 ligand (KIR3DL1+/HLA-Bw4+ genotype) had improved clinical outcomes if randomized to immunotherapy regimens, as compared to patients with the KIR3DL1+/HLA-Bw4+ genotype randomized to the non-immunotherapy regimen. Conversely, patients that did not have the KIR3DL1+/HLA-Bw4+ genotype showed no evidence of a difference in outcome if receiving the immunotherapy vs. no-immunotherapy. For each trial, HLA-Bw4 status was determined by assessing the genotypes of three separate isoforms of HLA-Bw4: (1) HLA-B-Bw4 with threonine at amino acid 80 (B-Bw4-T80); (2) HLA-B-Bw4 with isoleucine at amino acid 80 (HLA-B-Bw4-I80); and (3) HLA-A with a Bw4 epitope (HLA-A-Bw4). Here, we report on associations with clinical outcome for patients with KIR3DL1 and these separate isoforms of HLA-Bw4. Patients randomized to immunotherapy with KIR3DL1+/A-Bw4+ or with KIR3DL1+/B-Bw4-T80+ had better outcome vs. those randomized to no-immunotherapy, whereas for those with KIR3DL1+/B-Bw4-I80+ there was no evidence of a difference based on immunotherapy vs. no-immunotherapy. Additionally, we observed differences within treatment types (either within immunotherapy or no-immunotherapy) that were associated with the genotype status for the different KIR3DL1/HLA-Bw4-isoforms. These studies suggest that specific HLA-Bw4 isoforms may differentially influence response to these mAb-based immunotherapy, further confirming the involvement of KIR-bearing cells in tumor-reactive mAb-based cancer immunotherapy. |
| first_indexed | 2024-12-21T11:42:44Z |
| format | Article |
| id | doaj.art-d5bf7e8e13a14ddfb5d4f0085470960e |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-12-21T11:42:44Z |
| publishDate | 2017-06-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-d5bf7e8e13a14ddfb5d4f0085470960e2022-12-21T19:05:16ZengFrontiers Media S.A.Frontiers in Immunology1664-32242017-06-01810.3389/fimmu.2017.00675264188HLA-Bw4-I-80 Isoform Differentially Influences Clinical Outcome As Compared to HLA-Bw4-T-80 and HLA-A-Bw4 Isoforms in Rituximab or Dinutuximab-Based Cancer ImmunotherapyAmy K. Erbe0Wei Wang1Patrick K. Reville2Lakeesha Carmichael3KyungMann Kim4Eneida A. Mendonca5Yiqiang Song6Jacquelyn A. Hank7Wendy B. London8Arlene Naranjo9Fangxin Hong10Michael D. Hogarty11John M. Maris12Julie R. Park13Julie R. Park14M. F. Ozkaynak15Jeffrey S. Miller16Andrew L. Gilman17Brad Kahl18Alice L. Yu19Alice L. Yu20Paul M. Sondel21Paul M. Sondel22Department of Human Oncology, University of Wisconsin, Madison, WI, United StatesDepartment of Human Oncology, University of Wisconsin, Madison, WI, United StatesDepartment of Human Oncology, University of Wisconsin, Madison, WI, United StatesDepartment of Biostatistics and Medical Informatics, University of Wisconsin, Madison, WI, United StatesDepartment of Biostatistics and Medical Informatics, University of Wisconsin, Madison, WI, United StatesDepartment of Biostatistics and Medical Informatics, University of Wisconsin, Madison, WI, United StatesDepartment of Biostatistics and Medical Informatics, University of Wisconsin, Madison, WI, United StatesDepartment of Human Oncology, University of Wisconsin, Madison, WI, United StatesDana-Farber Cancer Institute/Boston Children’s Cancer and Blood Disorder Center, Harvard Medical School, Boston, MA, United StatesCOG Statistics and Data Center, Department of Biostatistics, University of Florida, Gainesville, FL, United StatesDepartment of Biostatistics, Harvard University, Dana Farber Cancer Institute, Boston, MA, United StatesChildren’s Hospital of Philadelphia, University of Pennsylvania School of Medicine, Philadelphia, PA, United StatesProvenance Biopharmaceuticals, Carlisle, MA, United StatesSeattle Children’s Hospital/University, Seattle, WA, United StatesUniversity of Washington, Seattle, WA, United States0New York Medical College, Valhalla, NY, United States1Department of Medicine, University of Minnesota, Minneapolis, MN, United States2Levine Children’s Hospital, Charlotte, NC, United States3Department of Medicine, Washington University, St. Louis, MO, United States4Department of Pediatrics, Hematology/Oncology, Moores Cancer Center, University of California San Diego, San Diego, CA, United States5Institute of Stem Cell and Translational Cancer Research, Chang Gung Memorial Hospital, Taoyuan, TaiwanDepartment of Human Oncology, University of Wisconsin, Madison, WI, United States6Department of Pediatrics, University of Wisconsin-Madison, Madison, WI, United StatesKiller-cell immunoglobulin-like receptors (KIRs) are a family of glycoproteins expressed primarily on natural killer cells that can regulate their function. Inhibitory KIRs recognize MHC class I molecules (KIR-ligands) as ligands. We have reported associations of KIRs and KIR-ligands for patients in two monoclonal antibody (mAb)-based trials: (1) A Children’s Oncology Group (COG) trial for children with high-risk neuroblastoma randomized to immunotherapy treatment with dinutuximab (anti-GD2 mAb) + GM-CSF + IL-2 + isotretinion or to treatment with isotretinoin alone and (2) An Eastern Cooperative Oncology Group (ECOG) trial for adults with low-tumor burden follicular lymphoma responding to an induction course of rituximab (anti-CD20 mAb) and randomized to treatment with maintenance rituximab or no-maintenance rituximab. In each trial, certain KIR/KIR-ligand genotypes were associated with clinical benefit for patients randomized to immunotherapy treatment (immunotherapy in COG; maintenance rituximab in ECOG) as compared to patients that did not receive the immunotherapy [isotretinoin alone (COG); no-maintenance (ECOG)]. Namely, patients with both KIR3DL1 and its HLA-Bw4 ligand (KIR3DL1+/HLA-Bw4+ genotype) had improved clinical outcomes if randomized to immunotherapy regimens, as compared to patients with the KIR3DL1+/HLA-Bw4+ genotype randomized to the non-immunotherapy regimen. Conversely, patients that did not have the KIR3DL1+/HLA-Bw4+ genotype showed no evidence of a difference in outcome if receiving the immunotherapy vs. no-immunotherapy. For each trial, HLA-Bw4 status was determined by assessing the genotypes of three separate isoforms of HLA-Bw4: (1) HLA-B-Bw4 with threonine at amino acid 80 (B-Bw4-T80); (2) HLA-B-Bw4 with isoleucine at amino acid 80 (HLA-B-Bw4-I80); and (3) HLA-A with a Bw4 epitope (HLA-A-Bw4). Here, we report on associations with clinical outcome for patients with KIR3DL1 and these separate isoforms of HLA-Bw4. Patients randomized to immunotherapy with KIR3DL1+/A-Bw4+ or with KIR3DL1+/B-Bw4-T80+ had better outcome vs. those randomized to no-immunotherapy, whereas for those with KIR3DL1+/B-Bw4-I80+ there was no evidence of a difference based on immunotherapy vs. no-immunotherapy. Additionally, we observed differences within treatment types (either within immunotherapy or no-immunotherapy) that were associated with the genotype status for the different KIR3DL1/HLA-Bw4-isoforms. These studies suggest that specific HLA-Bw4 isoforms may differentially influence response to these mAb-based immunotherapy, further confirming the involvement of KIR-bearing cells in tumor-reactive mAb-based cancer immunotherapy.http://journal.frontiersin.org/article/10.3389/fimmu.2017.00675/fullKIRKIR-ligandHLA-Bw4HLAMHC class Inatural killer cells |
| spellingShingle | Amy K. Erbe Wei Wang Patrick K. Reville Lakeesha Carmichael KyungMann Kim Eneida A. Mendonca Yiqiang Song Jacquelyn A. Hank Wendy B. London Arlene Naranjo Fangxin Hong Michael D. Hogarty John M. Maris Julie R. Park Julie R. Park M. F. Ozkaynak Jeffrey S. Miller Andrew L. Gilman Brad Kahl Alice L. Yu Alice L. Yu Paul M. Sondel Paul M. Sondel HLA-Bw4-I-80 Isoform Differentially Influences Clinical Outcome As Compared to HLA-Bw4-T-80 and HLA-A-Bw4 Isoforms in Rituximab or Dinutuximab-Based Cancer Immunotherapy Frontiers in Immunology KIR KIR-ligand HLA-Bw4 HLA MHC class I natural killer cells |
| title | HLA-Bw4-I-80 Isoform Differentially Influences Clinical Outcome As Compared to HLA-Bw4-T-80 and HLA-A-Bw4 Isoforms in Rituximab or Dinutuximab-Based Cancer Immunotherapy |
| title_full | HLA-Bw4-I-80 Isoform Differentially Influences Clinical Outcome As Compared to HLA-Bw4-T-80 and HLA-A-Bw4 Isoforms in Rituximab or Dinutuximab-Based Cancer Immunotherapy |
| title_fullStr | HLA-Bw4-I-80 Isoform Differentially Influences Clinical Outcome As Compared to HLA-Bw4-T-80 and HLA-A-Bw4 Isoforms in Rituximab or Dinutuximab-Based Cancer Immunotherapy |
| title_full_unstemmed | HLA-Bw4-I-80 Isoform Differentially Influences Clinical Outcome As Compared to HLA-Bw4-T-80 and HLA-A-Bw4 Isoforms in Rituximab or Dinutuximab-Based Cancer Immunotherapy |
| title_short | HLA-Bw4-I-80 Isoform Differentially Influences Clinical Outcome As Compared to HLA-Bw4-T-80 and HLA-A-Bw4 Isoforms in Rituximab or Dinutuximab-Based Cancer Immunotherapy |
| title_sort | hla bw4 i 80 isoform differentially influences clinical outcome as compared to hla bw4 t 80 and hla a bw4 isoforms in rituximab or dinutuximab based cancer immunotherapy |
| topic | KIR KIR-ligand HLA-Bw4 HLA MHC class I natural killer cells |
| url | http://journal.frontiersin.org/article/10.3389/fimmu.2017.00675/full |
| work_keys_str_mv | AT amykerbe hlabw4i80isoformdifferentiallyinfluencesclinicaloutcomeascomparedtohlabw4t80andhlaabw4isoformsinrituximabordinutuximabbasedcancerimmunotherapy AT weiwang hlabw4i80isoformdifferentiallyinfluencesclinicaloutcomeascomparedtohlabw4t80andhlaabw4isoformsinrituximabordinutuximabbasedcancerimmunotherapy AT patrickkreville hlabw4i80isoformdifferentiallyinfluencesclinicaloutcomeascomparedtohlabw4t80andhlaabw4isoformsinrituximabordinutuximabbasedcancerimmunotherapy AT lakeeshacarmichael hlabw4i80isoformdifferentiallyinfluencesclinicaloutcomeascomparedtohlabw4t80andhlaabw4isoformsinrituximabordinutuximabbasedcancerimmunotherapy AT kyungmannkim hlabw4i80isoformdifferentiallyinfluencesclinicaloutcomeascomparedtohlabw4t80andhlaabw4isoformsinrituximabordinutuximabbasedcancerimmunotherapy AT eneidaamendonca hlabw4i80isoformdifferentiallyinfluencesclinicaloutcomeascomparedtohlabw4t80andhlaabw4isoformsinrituximabordinutuximabbasedcancerimmunotherapy AT yiqiangsong hlabw4i80isoformdifferentiallyinfluencesclinicaloutcomeascomparedtohlabw4t80andhlaabw4isoformsinrituximabordinutuximabbasedcancerimmunotherapy AT jacquelynahank hlabw4i80isoformdifferentiallyinfluencesclinicaloutcomeascomparedtohlabw4t80andhlaabw4isoformsinrituximabordinutuximabbasedcancerimmunotherapy AT wendyblondon hlabw4i80isoformdifferentiallyinfluencesclinicaloutcomeascomparedtohlabw4t80andhlaabw4isoformsinrituximabordinutuximabbasedcancerimmunotherapy AT arlenenaranjo hlabw4i80isoformdifferentiallyinfluencesclinicaloutcomeascomparedtohlabw4t80andhlaabw4isoformsinrituximabordinutuximabbasedcancerimmunotherapy AT fangxinhong hlabw4i80isoformdifferentiallyinfluencesclinicaloutcomeascomparedtohlabw4t80andhlaabw4isoformsinrituximabordinutuximabbasedcancerimmunotherapy AT michaeldhogarty hlabw4i80isoformdifferentiallyinfluencesclinicaloutcomeascomparedtohlabw4t80andhlaabw4isoformsinrituximabordinutuximabbasedcancerimmunotherapy AT johnmmaris hlabw4i80isoformdifferentiallyinfluencesclinicaloutcomeascomparedtohlabw4t80andhlaabw4isoformsinrituximabordinutuximabbasedcancerimmunotherapy AT julierpark hlabw4i80isoformdifferentiallyinfluencesclinicaloutcomeascomparedtohlabw4t80andhlaabw4isoformsinrituximabordinutuximabbasedcancerimmunotherapy AT julierpark hlabw4i80isoformdifferentiallyinfluencesclinicaloutcomeascomparedtohlabw4t80andhlaabw4isoformsinrituximabordinutuximabbasedcancerimmunotherapy AT mfozkaynak hlabw4i80isoformdifferentiallyinfluencesclinicaloutcomeascomparedtohlabw4t80andhlaabw4isoformsinrituximabordinutuximabbasedcancerimmunotherapy AT jeffreysmiller hlabw4i80isoformdifferentiallyinfluencesclinicaloutcomeascomparedtohlabw4t80andhlaabw4isoformsinrituximabordinutuximabbasedcancerimmunotherapy AT andrewlgilman hlabw4i80isoformdifferentiallyinfluencesclinicaloutcomeascomparedtohlabw4t80andhlaabw4isoformsinrituximabordinutuximabbasedcancerimmunotherapy AT bradkahl hlabw4i80isoformdifferentiallyinfluencesclinicaloutcomeascomparedtohlabw4t80andhlaabw4isoformsinrituximabordinutuximabbasedcancerimmunotherapy AT alicelyu hlabw4i80isoformdifferentiallyinfluencesclinicaloutcomeascomparedtohlabw4t80andhlaabw4isoformsinrituximabordinutuximabbasedcancerimmunotherapy AT alicelyu hlabw4i80isoformdifferentiallyinfluencesclinicaloutcomeascomparedtohlabw4t80andhlaabw4isoformsinrituximabordinutuximabbasedcancerimmunotherapy AT paulmsondel hlabw4i80isoformdifferentiallyinfluencesclinicaloutcomeascomparedtohlabw4t80andhlaabw4isoformsinrituximabordinutuximabbasedcancerimmunotherapy AT paulmsondel hlabw4i80isoformdifferentiallyinfluencesclinicaloutcomeascomparedtohlabw4t80andhlaabw4isoformsinrituximabordinutuximabbasedcancerimmunotherapy |